Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 1;14(10):7073-7085.
doi: 10.21037/qims-24-879. Epub 2024 Sep 14.

Efficacy and safety of a novel vena cava filter on pulmonary embolism prophylaxis: a prospective, multicenter, randomized, parallel, positive-controlled, noninferiority clinical trial

Affiliations

Efficacy and safety of a novel vena cava filter on pulmonary embolism prophylaxis: a prospective, multicenter, randomized, parallel, positive-controlled, noninferiority clinical trial

Maofeng Gong et al. Quant Imaging Med Surg. .

Abstract

Background: There are different types of vena cava filter (VCF) available in clinical practice. However, limited data exist to determine whether one type is superior to another, and no single VCF is universally recommended in clinical guidelines. The objective of this study was to investigate the safety and efficacy of a novel VCF, Octoparms, for the prevention of pulmonary embolism (PE) and to compare it with the Celect filter.

Methods: This multicenter, randomized, open-label, parallel, positive-controlled, noninferiority trial was conducted in 10 centers across 6 provinces in China from October 2017 to March 2019. Patients who had confirmed lower extremity deep vein thrombosis or PE or who were at risk of PE with a clinical indication for VCF placement due to contraindication to or failure of anticoagulant therapy were included in the trial. The sample size for this trial was based on the assumption that the clinical success rate would be 95% and the noninferiority margin would be 10% for both filters. Each patient underwent baseline testing and was randomized using a web-based central system. Any additional interventions or standard treatments patients received along with the VCF placement were recorded. The primary endpoint was the overall clinical success rate, including technical and clinical success of filter placement and retrieval. The secondary endpoint was the safety of filter placement and retrieval, encompassing procedure-related and filter-related complications.

Results: A total of 188 patients were included and were divided into two groups: the Octoparms group (n=94) and the Celect group (n=94). Baseline characteristics and demographics were comparable between the two groups (P>0.05). Technical and clinical success rates for filter placement were achieved in 100% (188/188) of patients. The median dwelling time was 12.0 days (range, 4-190 days). Ten VCFs were left in situ as permanent devices. Of the remaining 178 patients, technical success and clinical success rates for filter retrieval were both achieved in 100% of cases (178/178). Clinical success rates were 92.6% (87/94) for the Octoparms group and 96.8% (91/94) for the Celect group, with a difference of -4.2% (hazard ratio 2.441, 95% confidence interval 0.612-9.741; P=0.206). The lower limit was greater than the noninferiority margin of -10%. Eight patients experienced a total of eight procedure-related complications. No filter-related complications, such as migration, deformation, inferior vena cava (IVC) penetration, peripheral organ damage, or IVC stenosis/occlusion, were observed (P>0.05).

Conclusions: The Octoparms filter exhibited a high rate of clinical success and a low rate of complications during placement and retrieval, demonstrating noninferiority to the Celect filter.

Keywords: Pulmonary embolism (PE); inferior vena cava (IVC); safety; treatment outcome; vena cava filter (VCF).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://qims.amegroups.com/article/view/10.21037/qims-24-879/coif). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
The study flowchart of the inclusion and exclusion of patients with LEDVT who received VCFs. LEDVT, lower extremity deep vein thrombosis; VCF, vena cava filter.
Figure 2
Figure 2
A schematic representation of the Octoparms filter and the procedure of its placement and retrieval. (A) Schematic of the design and structure of the Octoparms filter, showcasing its key features and components. (B) The filter is placed into the designated location. (C) Venography following the filter placement showing a well-performed placement and an unobstructed blood flow. (D) Retrieval procedure.
Figure 3
Figure 3
Dwelling time before VCF retrieval. VCF, vena cava filter.
Figure 4
Figure 4
The distributions of filter tilt angle at the time of placement and retrieval for both groups. (A) In the Octoparms group, there was no statistically significant difference between filter tilt angles at the time of placement and the time of retrieval (P=0.61). (B) In the Celect group, there was statistically significant difference between filter tilt angles at the time of placement and the time of retrieval (P<0.05).

References

    1. Kaufman JA, Barnes GD, Chaer RA, Cuschieri J, Eberhardt RT, Johnson MS, Kuo WT, Murin S, Patel S, Rajasekhar A, Weinberg I, Gillespie DL. Society of Interventional Radiology Clinical Practice Guideline for Inferior Vena Cava Filters in the Treatment of Patients with Venous Thromboembolic Disease: Developed in collaboration with the American College of Cardiology, American College of Chest Physicians, American College of Surgeons Committee on Trauma, American Heart Association, Society for Vascular Surgery, and Society for Vascular Medicine. J Vasc Interv Radiol 2020;31:1529-44. 10.1016/j.jvir.2020.06.014 - DOI - PubMed
    1. Bikdeli B, Wang Y, Jimenez D, Parikh SA, Monreal M, Goldhaber SZ, Krumholz HM. Pulmonary Embolism Hospitalization, Readmission, and Mortality Rates in US Older Adults, 1999-2015. JAMA 2019;322:574-6. 10.1001/jama.2019.8594 - DOI - PMC - PubMed
    1. Sheahan KP, Tong E, Lee MJ. A review of inferior vena cava filters. Br J Radiol 2023;96:20211125. 10.1259/bjr.20211125 - DOI - PMC - PubMed
    1. Jia Z, Wu A, Tam M, Spain J, McKinney JM, Wang W. Caval Penetration by Inferior Vena Cava Filters: A Systematic Literature Review of Clinical Significance and Management. Circulation 2015;132:944-52. 10.1161/CIRCULATIONAHA.115.016468 - DOI - PubMed
    1. Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral FG, Huet Y, Simonneau G. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998;338:409-15. 10.1056/NEJM199802123380701 - DOI - PubMed

LinkOut - more resources